BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36302223)

  • 1. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020.
    Qian MF; Betancourt NJ; Pineda A; Maloney NJ; Nguyen KA; Reddy SA; Hall ET; Swetter SM; Zaba LC
    Oncologist; 2023 Mar; 28(3):268-275. PubMed ID: 36302223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
    van Boemmel-Wegmann S; Brown JD; Diaby V; Huo J; Silver N; Park H
    JCO Oncol Pract; 2022 Jan; 18(1):e163-e174. PubMed ID: 34228489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
    Gupta M; Stukalin I; Meyers D; Goutam S; Heng DYC; Cheng T; Monzon J; Navani V
    JAMA Netw Open; 2023 Jun; 6(6):e2319607. PubMed ID: 37351883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States.
    Klink AJ; Chmielowski B; Feinberg B; Ahsan S; Nero D; Liu FX
    J Manag Care Spec Pharm; 2019 Aug; 25(8):869-877. PubMed ID: 30945965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
    Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
    Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
    Long GV; Arance A; Mortier L; Lorigan P; Blank C; Mohr P; Schachter J; Grob JJ; Lotem M; Middleton MR; Neyns B; Steven N; Ribas A; Walpole E; Carlino MS; Lebbe C; Sznol M; Jensen E; Leiby MA; Ibrahim N; Robert C
    Ann Oncol; 2022 Feb; 33(2):204-215. PubMed ID: 34710571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
    Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
    Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.
    Ghate SR; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
    Curr Med Res Opin; 2018 Dec; 34(12):2169-2176. PubMed ID: 30009647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
    Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M
    BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
    Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
    J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
    [No Abstract]   [Full Text] [Related]  

  • 14. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
    Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.
    Freeman M; Betts KA; Jiang S; Du EX; Gupte-Singh K; Lu Y; Rao S; Shoushtari AN
    Adv Ther; 2019 Oct; 36(10):2783-2796. PubMed ID: 31440980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.
    Uhara H
    Int J Clin Oncol; 2019 Dec; 24(12):1508-1514. PubMed ID: 29470725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
    Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
    Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
    J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.